IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

Pomalyst (pomalidomide) is a prescription drug that’s used to treat ... Pomalyst works to treat multiple myeloma in several ways: Pomalyst stops new cancer cells from forming by blocking the ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer treatment known as Bispecific T-Cell Engager (BiTE) therapies on Feb. 11, 2025 ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy. It is planned that the drug using the new technology will pass all the necessary clinical trials and ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new ...